<DOC>
	<DOCNO>NCT02902601</DOCNO>
	<brief_summary>The primary purpose study investigate safety tolerability JNJ 54175446 participant Major Depressive Disorder ( MDD ) .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacodynamics JNJ-54175446 Participants With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Body mass index ( BMI ) must 18 32 kilogram per square meter ( kg/m^2 ) inclusive Related symptom depression : Participant must meet Diagnostic Statistical Manual Mental Disorders ( DSM ) IV V diagnostic criterion Major Depressive Disorder [ MDD ] ( International Classification Diseases ( ICD ) code F32.x F33.x ) , without psychotic feature , confirm MINI 6.0 ; participant must IDSC30 total score great equal ( &gt; = ) 30 use semistructured interview guide IDSC30 Participant , episode depression , treatment na√Øve OR treat one Selective serotonin reuptake inhibitor ( SSRI ) minimum 6 week maximum 6 month , subject treat adequate dose , show partial response enrolment A woman childbearing potential must negative serum pregnancy test screen negative urine pregnancy test upon admission A woman must agree donate egg ( ovum , oocytes ) purpose assist reproduction study least 3 month receive last dose study drug Has primary DSMIV V diagnosis general anxiety disorder ( GAD ) , panic disorder , obsessive compulsive disorder , posttraumatic stress disorder , anorexia nervosa , bulimia nervosa . Participants comorbid GAD , social anxiety disorder , panic disorder MDD consider primary diagnosis exclude Has length current major depressive episode great ( &gt; ) 24 month despite adequate treatment Has fail 2 treatment different pharmacological mode action despite adequate dose duration previous , current depressive episode Participant history substance use disorder accord DSMV criterion , except nicotine caffeine , within 6 month Screening . However , participant complete treatment ( alcohol ) addiction 8 week prior first dose administration continuous control study center , may include risk fall back consider minimal significant abnormality show clinical laboratory predose safety assessment Obstructive sleep apnea/hypopnea ( apnea/hypopnea index &gt; 10 ) restless legs syndrome ( periodic leg movement arousal index &gt; 15 ) assess first second polysomnography ( PSG ) record screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>